Please assess the completion status of the following clinical trial:

Trial Title: Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic evidence of invasive breast cancer~  * Stage II-III disease~ * Resectable disease~* Must have a primary tumor estimated by mammogram, ultrasound or palpation to be ≥ 3 cm and/or palpable axillary nodes \> 1 cm for whom neoadjuvant chemotherapy is appropriate~* ECOG performance status 0-1~* Absolute granulocyte count \> 2,000/mm\^3~* Platelet count \> 100,000/mm\^3~* Serum bilirubin \< 1.5 times upper limit of normal (ULN)~* Serum creatinine \< 1.5 times ULN~* Fertile patients must use effective contraception during and for 3 months after completion of study therapy~* At least 2 weeks since prior treatment with cyclooxygenase (COX)-2 inhibitors~Exclusion Criteria:~* Not pregnant or nursing/negative pregnancy test~* No allergies to sulfa medication, aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)~* No uncontrolled concurrent illness that might jeopardize the patient's ability to receive the chemotherapy program outlined in this protocol, including any of the following:~  * Active infection requiring intravenous antibiotics~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Serious, uncontrolled cardiac arrhythmia~* No other prior malignancy except for adequately treated basal cell or squamous cell skin cancer, noninvasive carcinomas, or other cancers from which the patient has been disease-free for at least 5 years~* No prior chemotherapy or radiation therapy for ipsilateral breast cancer~* No concurrent sorivudine or brivudine to treat herpes simplex or herpes zoster viral infections~* No concurrent participation in another therapeutic clinical trial

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Celecoxib (Type: EXPERIMENTAL): •Neoadjuvant chemotherapy: Patients receive docetaxel IV over 1 hour on days 1, 8, and 15, oral capecitabine twice daily on days 1-14, and oral celecoxib twice daily on days 1-21. Courses repeat every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV once daily on day 1, oral celecoxib twice daily on days 1-14, and filgrastim subcutaneously once daily on days 3-10. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Celecoxib is stopped one week prior to surgery.~•Surgery: Patients undergo definitive surgery (either modified radical mastectomy or lumpectomy combined with axillary node dissection). Patients may also undergo adjuvant radiotherapy and hormonal therapy at the discretion of multidisciplinary breast team.

Based on this trial design, predict the completion outcome and termination type (if applicable).